Skye BioscienceSKYE
About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Employees: 11
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,967% more funds holding
Funds holding: 3 [Q1] → 62 (+59) [Q2]
558% more capital invested
Capital invested by funds: $31.4M [Q1] → $207M (+$175M) [Q2]
400% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 5 (+4) [Q2]
91.98% more ownership
Funds ownership: 0% [Q1] → 91.98% (+91.98%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0% more call options, than puts
Call options by funds: $9K | Put options by funds: $9K
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Scotiabank George Farmer 15% 1-year accuracy 3 / 20 met price target | 250%upside $20 | Sector Outperform Initiated | 30 Sept 2024 |
Piper Sandler Edward Tenthoff 40% 1-year accuracy 16 / 40 met price target | 250%upside $20 | Overweight Reiterated | 20 Sept 2024 |
Cantor Fitzgerald Kristen Kluska 60% 1-year accuracy 62 / 104 met price target | 145%upside $14 | Overweight Reiterated | 20 Sept 2024 |
JMP Securities Jonathan Wolleben 58% 1-year accuracy 42 / 72 met price target | 163%upside $15 | Market Outperform Initiated | 10 Sept 2024 |
Cantor Fitzgerald Kristen Kluska 60% 1-year accuracy 62 / 104 met price target | 145%upside $14 | Overweight Reiterated | 9 Sept 2024 |
Financial journalist opinion
Based on 4 articles about SKYE published over the past 30 days
